MedTrace Logo

A Placebo-Controlled Trial of D-Cycloserine and Exposure Therapy for Combat-PTSD

NCT00371176 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2014-02-04

Study results available
· View outcomes & findings →

Summary

The primary aim of this project is to examine whether administration of D-Cycloserine (DCS), a partial N-methyl-D-aspartate (NMDA) receptor agonist that has been shown to facilitate fear extinction, enhances the therapeutic benefit of exposure-based cognitive behavioral therapy (CBT) in OEF/OIF veterans with PTSD.

Conditions

  • Combat Disorders
  • Stress Disorders, Post-Traumatic

Interventions

BEHAVIORAL

Exposure therapy

A manualized form of treatment that involves vividly visualizing indexed trauma with the guidance of a therapist

DRUG

D-Cycloserine

A partial NMDA agonist that has been shown in human trials to facilitate and strengthen extinction with CBT.

OTHER

Placebo pill

Sponsors & Collaborators

Principal Investigators

  • Brett T. Litz, PhD · VA Boston Health Care System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2011-09-30
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00371176 on ClinicalTrials.gov